학술논문

A study of elective genome sequencing and pharmacogenetic testing in an unselected population.
Document Type
Article
Source
Molecular Genetics & Genomic Medicine. Sep2021, Vol. 9 Issue 9, p1-25. 25p.
Subject
*NUCLEOTIDE sequencing
*PHARMACOGENOMICS
*PHENOTYPES
*CLINICAL indications
*GENOMICS
*HEMATOPOIESIS
Language
ISSN
2324-9269
Abstract
Background: Genome sequencing (GS) of individuals without a medical indication, known as elective GS, is now available at a number of centers around the United States. Here we report the results of elective GS and pharmacogenetic panel testing in 52 individuals at a private genomics clinic in Alabama. Methods: Individuals seeking elective genomic testing and pharmacogenetic testing were recruited through a private genomics clinic in Huntsville, AL. Individuals underwent clinical genome sequencing with a separate pharmacogenetic testing panel. Results: Six participants (11.5%) had pathogenic or likely pathogenic variants that may explain one or more aspects of their medical history. Ten participants (19%) had variants that altered the risk of disease in the future, including two individuals with clonal hematopoiesis of indeterminate potential. Forty‐four participants (85%) were carriers of a recessive or X‐linked disorder. All individuals with pharmacogenetic testing had variants that affected current and/or future medications. Conclusion: Our study highlights the importance of collecting detailed phenotype information to interpret results in elective GS. [ABSTRACT FROM AUTHOR]